依普利酮在国内什么时候上市呢？

Developed by Pfizer of the United States, it was first marketed in the United States in 2002. It is mainly used clinically to treat hypertension. In 2003, the FDA approved eplerenone for the treatment of heart failure after acute myocardial infarction. In 2002, eplerenone was approved for clinical use by the State Food and Drug Administration, but it has not been marketed in my country, so Chinese patients cannot currently buy this drug in domestic pharmacies.

Eplerenone binds to mineralocorticoid receptors, thereby blocking the binding of aldosterone, a component of the renin-angiotensin-aldosterone system (RAAS). Aldosterone synthesis occurs primarily in the adrenal gland and is regulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in epithelial tissues (such as the kidneys) and non-epithelial tissues (such as the heart, blood vessels, and brain) and increases blood pressure by inducing sodium reabsorption and possibly other mechanisms.

Eplerenone can be used for congestive heart failure after acute myocardial infarction. Eplerenone can improve the quality of life of patients with left ventricular dysfunction (ejection fraction ≤ 40%). Clinical trials have proven that this product can also be used for heart failure after acute myocardial infarction. For heart failure, the commonly used domestic aldosterone receptor antagonist spironolactone has a significant protective effect on the cardiovascular system, but its sex hormone-related side effects limit its application. As a new generation of selective aldosterone receptor antagonist, eplerenone provides a new method for the treatment of cardiovascular diseases.

Studies have shown that eplerenone can cause a sustained increase in plasma renin and serum aldosterone, and at the same time block the feedback regulatory effect of aldosterone. However, the increase in plasma renin activity and the increase in systemic circulation aldosterone levels will not offset the blood pressure control effect of this product. Eplerenone and spironolactone work on the same principle. Long-term use of spironolactone can cause endocrine disorders, but it has the advantages of good tolerance and few side effects, avoiding the side effects of endocrine disorders.